Psycheceutical Bioscience Inc. (OTCPK: BWVI) is a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments. Powered by a team of FDA drug development veterans, leading mental health scientists, and a network of international partners, Psycheceutical is on a mission to develop precision dosing technologies and more effective tools to provide the safe and effective delivery of psychedelic pharmaceutical medicines.

Our next-generation patented delivery technologies, via systemic and non-systemic routes of administration, are expected to allow psychedelics to be administered without unwanted side effects and toxicity, providing direct and profound benefits to those suffering from mental health disorders.


2 Patented Drug
Delivery Technologies

designed to increase the safety and efficacy of psychedelic therapeutics while eliminating hallucinations and side effects.

2 Active Clinical
Research Programs

NeuroDirect™ ketamine topical for PTSD — clinical trials Q2 2023.

Second drug for the treatment of addiction in pre-clinical stage.

An Experienced,
Visionary Team

consisting of medical specialists, biotechnology scientists, FDA regulatory advisors, psychedelic industry insiders, and business development experts.


02/15/2023 in Press Releases

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD

Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in Australia
Read More
02/02/2023 in Press Releases

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD
Read More
01/26/2023 in Press Releases

Psycheceutical Bioscience Files Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD)
Read More


Latest Events

Upcoming Events



Investors are invited to learn more about Psycheceutical, and stay up to date on the latest news, events, and regulatory updates by contacting our team via the accompanying contact form.